

PRESS RELEASE 03/02/2020

Former CMO of SYNLAB Suisse moves to AVA LifeScience

AVA LifeScience - the young development company of cutting-edge technologies for precision medicine strengthens the management team around Ulrich Birsner (CEO), Marc Kessemeier (CFO) and Dr. Marcus Dühren- von Minden (CSO). The expansion prepares the company for upcoming challenges in the growing customized therapy market. As Chief Medical Officer (CMO), Dr. med. Dr. phil.-nat. Philippe Haas will be responsible for the development of medical strategic concepts and preparing new medical products for their market entry. He will also assume responsibility for the subsidiary AVA Therapeutics GmbH, from where AVA-NextGenMonoclonals™ antibodies are further developed for their use in precision therapy. Dr. Dr. Haas will also build the department of artificial intelligence. Focus of the development activities will be on subgroup-stratification in the area of B-cell associated diseases to allow future target-oriented therapy-recommendations based on ApLife™ products.

Philippe Haas, who holds a doctorate in medicine and physics, has many years of experience in the healthcare sector and is an expert of information and technology transfer, technology scouting and medical artificial intelligence. His expertise includes the conception and ongoing implementation of new health-related technologies and measures, products and strategies for their implementation in the respective markets.

The specialist in general internal medicine is also experienced in molecular pathology (tumor microarrays), general surgery and as a PhD student of experimental physics in nano-optical biosensor technology for real-time determination of DNA and mRNA in liquids. As a military doctor, he spent several years working on a technology transfer project for the Swiss Army, including the American Special Operations Command in the field of prehospital emergency medicine (Tactical Combat Casualty Care, T3C). He is still serving in the Swiss Army and holds the rank of colonel. From 2016 until the end of February 2020, he was CMO of SYNLAB Suisse SA a diagnostics company, part of the largest laboratory service provider in Europe with over 19,000 employees.

About AVA LifeScience

AVA LifeScience is a young development company located in the BioMed region Freiburg. It develops effective methods for precision medicine of the coming century based on pinpoint monoclonal antibodies. The focus is on the combination of efficient therapy-oriented diagnostics with the respective precisely fitting therapeutic solution.

Further Information:

Dr. Nadja Höfs, Head of Marketing, AVA LifeScience GmbH
+49 (0)7666 9126380 | Nh@ava-lifescience.com